Johnson Chemical Pharmaceutical Works Co (4747) Fair Value & Analysis
Healthcare · TW · Market cap 4.4B TWD
Fair value as of: Jul 21, 2026
From 25 valuation models · updated 20 days ago
Fair value updated Jul 21, 2026, revised from 25.89 TWD to 12.95 TWD (−50.0%) since Jul 11, 2026. Share price +8.2% over the past month.
Below-average quality, and screening another 76% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (16.18 TWD). The favourable scenario is already priced in.
- Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 24.75 TWD – 110.01 TWD · fair‑value band 9.71 TWD – 16.18 TWD · the 54.10 TWD price screens above the 12.95 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Johnson Chemical Pharmaceutical Works Co (4747) currently trades at 54.10 TWD, while our model-based Fair Value estimate is 12.95 TWD, implying the stock looks roughly 76.1% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Johnson Chemical Pharmaceutical Works Co generated revenue of 570M TWD at a net margin of 17.3%. Revenue declined 0.1% year over year. It earns a return on equity of 5.6%. The stock trades on a trailing P/E of 45.5. Fundamentals as of Jul 21, 2026
Our scenario range runs from 9.71 TWD (bear case) to 16.18 TWD (bull case); at 54.10 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 33% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -76%, 4747 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: DCF Models (18.63 TWD) versus Earnings-Based (10.50 TWD). Highest evidence: Growth DCF (80).
Notify me when 4747 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Johnson Chemical Pharmaceutical Works Co., Ltd. manufactures, imports, and sells pharmaceutical ingredients, materials and products in Taiwan. The company manufactures drugs in a variety of forms, such as solid dosage form, capsule, tablet, and powder and granule, as well as nasal spray forms.
Full company description
Johnson Chemical Pharmaceutical Works Co., Ltd. manufactures, imports, and sells pharmaceutical ingredients, materials and products in Taiwan. The company manufactures drugs in a variety of forms, such as solid dosage form, capsule, tablet, and powder and granule, as well as nasal spray forms. It offers its products in various therapeutic areas, including central nervous system, respiratory, cardiovascular, gastrointestinal, endocrine system, vitamins, anti-inflammatory, cough and cold, pain reliever, etc. The company was founded in 1959 and is based in New Taipei City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Johnson Chemical Pharmaceutical Works Co reported revenue of 570M TWD in FY2025 versus 411M TWD in FY2021, a compound +8.5%/yr. Reported net income was 53.5M TWD in FY2025, compounding +2.2%/yr from FY2021.
4747 screens 76% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Johnson Chemical Pharmaceutical Works Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Johnson Chemical Pharmaceutical Works Co (4747) overvalued or undervalued?
What is the fair value of 4747?
What is the quality score of 4747?
What is the revenue of Johnson Chemical Pharmaceutical Works Co (4747)?
What is the net profit margin of 4747?
Does Johnson Chemical Pharmaceutical Works Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Johnson Chemical Pharmaceutical Works Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.